Fibrous dysplasia of bone /McCune Albright syndrome (FD/MAS) is a rare bone disease caused by somatic mutations in GNAS gene. This GNAS mutation predisposes to cancers, including breast cancer, thyroid cancer, chondrosarcoma and osteosarcoma, as well as biliary tract anomalies, liver-tumors or pancreatic tumors - IPMNs. Intraductal papillary and mucinous neoplasms of the pancreas (IPMN) are cystic intraepithelial ductal lesions developed at the expense of pancreatic ducts. They are pre-cancerous lesions, requiring monitoring and, in case of progression or malignant degeneration, surgical resection. Pancreatic MRI screening of patients with polyostotic FD and MAS is recommended. The aim of this study is to investigate the epidemiology and characteristics of these hepato-pancreato-biliary abnormalities (prevalence, age of onset, degeneration), based on magnetic resonance imaging (MRI) realized during the follow-up of patients with FD/MAS treated in a French FD expert center. A better understanding of these IPMNs and other digestive abnormalities will enable clinicians to improve the management and monitoring in this high-risk population.
Study Type
OBSERVATIONAL
Enrollment
545
Data collection from hepato-bilio-pancreatic Magnetic Resonance Imaging realized during the follow up of patients with Fibrous dysplasia of bone /McCune Albright syndrome
CHU Angers
Angers, France
NOT_YET_RECRUITINGGroupe Hospitalier Pellegrin - Chu
Bordeaux, France
NOT_YET_RECRUITINGCHU de Brest - Hôpital de la Cavale Blanche
Brest, France
NOT_YET_RECRUITINGChu de Caen Normandie
Caen, France
NOT_YET_RECRUITINGChu de Clermont-Ferrand
Clermont-Ferrand, France
NOT_YET_RECRUITINGChu de Lille
Lille, France
NOT_YET_RECRUITINGService Rhumatologie, pavillon F Hopital E. Herriot
Lyon, France
NOT_YET_RECRUITINGAssistance Publique - Hopitaux de Marseille (Ap-Hm
Marseille, France
NOT_YET_RECRUITINGChu de Montpellier
Montpellier, France
NOT_YET_RECRUITINGCHU de Nice
Nice, France
NOT_YET_RECRUITING...and 6 more locations
Describe hepato-bilio-pancreatic abnormalities in FD/MAS and estimate the prevalence of IPMN.
Hepato-bilio-pancreatic abnormalities (size, number, complications) will be described based on hepato-bilio-pancreatic MRI.
Time frame: hepato-bilio-pancreatic MRI performed from January 2002 until December 2024.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.